(Q37660907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Molecular predictors of response to trastuzumab and lapatinib in breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

4

Gabriel N Hortobagyi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

3

Mien-Chie Hung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Dihua Yu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

22 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

98-107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Enhanced anti-tumor effect of trastuzumab in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Gaining ground on breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Future issues in highly conformal radiotherapy for head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

HER2 status and benefit from adjuvant trastuzumab in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Untangling the ErbB signalling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Stromal gene expression predicts clinical outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Targeting the mTOR signaling network for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Characterization of immunotoxins active against ovarian cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.216

Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth

31 March 2020

1 reference

12 December 2020

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

1 reference

12 December 2020

Phase I and II clinical trials of trastuzumab

1 reference

12 December 2020

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

12 December 2020

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

1 reference

12 December 2020

p185HER2 signal transduction in breast cancer cells

1 reference

12 December 2020

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and

1 reference

12 December 2020

Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses

1 reference

12 December 2020

10.1038/NRCLINONC.2009.216

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20027191%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference